SS-31 10mg

$60.00

SS-31 is a cell permeable synthetic tetrapeptide from the Szeto-Schiller peptide series. Its international nonproprietary name is elamipretide, and it is described in the FDA label for the approved medicine Forzinity as a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane. Forzinity (elamipretide hydrochloride, Stealth BioTherapeutics) received FDA accelerated approval on September 19, 2025 for a single rare disease indication. That approval applies only to Forzinity. The lyophilized material on this page is a research chemical, is not Forzinity, and is not covered by that approval.

Purity: greater than or equal to 99.0 percent (HPLC tested)
Molecular target studied: cardiolipin in the inner mitochondrial membrane
Format: Lyophilized powder for laboratory research
Key Research Focus: mitochondrial bioenergetics, reactive oxygen species measurement and cellular senescence models
Storage: Store at minus 20 degrees Celsius, sealed and protected from light and moisture

Category: Peptides

Description

SS-31 (Elamipretide) Overview

SS-31 is a member of the Szeto-Schiller (SS) series of aromatic cationic tetrapeptides. In clinical and regulatory literature it is called elamipretide, and it has also appeared under the development names MTP-131 and Bendavia. It is cell permeable and, unlike antioxidants that act throughout the cell, it concentrates at the inner mitochondrial membrane, where it associates with cardiolipin. Cardiolipin is a phospholipid of the inner mitochondrial membrane that contributes to the organization of the electron transport chain, and the interaction between SS-31 and cardiolipin is the central subject of the published research on this peptide.

Regulatory status

Elamipretide is the active ingredient of an approved prescription medicine in the United States. The FDA granted accelerated approval to Forzinity (elamipretide hydrochloride, application NDA 215244, Stealth BioTherapeutics) on September 19, 2025, as a new molecular entity under priority review. The approved indication reads: Forzinity is a mitochondrial cardiolipin binder indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. The label states that this indication is approved under accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint, and that continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial. The label’s mechanism of action section describes Forzinity as a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial morphology and function.

That approval is specific to Forzinity, to its manufacturer and to Barth syndrome. It does not extend to this material, to any other presentation of elamipretide, or to any other condition. The material offered on this page is a laboratory research chemical. It is not Forzinity, it is not a licensed or authorized medicine in Canada or any other country, and it is not supplied for any medical purpose. No claim of benefit for any person or animal is made or implied.

Technical Specifications

Peptide name: SS-31
Synonyms: Elamipretide, MTP-131, Bendavia
CAS number: 736992-21-5 (free base)
Molecular formula: C32H49N9O5 (free base). The approved medicine uses the trihydrochloride salt, C32H49N9O5 plus 3HCl, molecular weight 749.2.
Molar mass: 639.8 g/mol (free base)
Sequence: D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH2. All residues have the L configuration except arginine, which has the D configuration.
Chemical name: L-phenylalaninamide, D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-
Purity: greater than or equal to 99.0 percent (determined by HPLC)
Appearance: White to off white lyophilized powder
Solubility: Freely soluble in water

Research Context

Reported areas of study, with the evidence level stated:

Cardiolipin association: biophysical and cell culture work has characterized the binding of SS-31 to cardiolipin in the inner mitochondrial membrane and the resulting effects on membrane organization.
Electron transport and reactive oxygen species: in vitro studies have measured electron transport chain activity and reactive oxygen species output in isolated mitochondria and cultured cells exposed to the peptide.
Animal models: rodent models of ischemia and reperfusion, kidney injury, heart failure and age related decline have been used to examine the peptide. These are animal findings and are not evidence of any effect in a person.
Human trials: elamipretide has been evaluated in human clinical trials. The only outcome that has supported a marketing authorization is the knee extensor muscle strength endpoint in Barth syndrome described under regulatory status above, and that approval was an accelerated approval on an intermediate endpoint.

Storage and Handling

Lyophilized powder: store at minus 20 degrees Celsius (minus 4 degrees Fahrenheit) for up to 36 months, sealed and protected from light and moisture.
Reconstituted solution: store at 4 degrees Celsius (39 degrees Fahrenheit), protected from light, for up to 21 days, and avoid repeated freeze and thaw cycles.
Handling: standard laboratory safety practice applies. This product is for laboratory research use only.

Testing and Quality Control

Every batch of SS-31 10mg undergoes:

HPLC (high performance liquid chromatography): purity reported as greater than or equal to 99.0 percent.
MS (mass spectrometry): confirms the molecular mass expected for the tetrapeptide, including the 2,6-dimethyltyrosine residue.
Appearance and identity checks on the lyophilized cake.

HPLC and mass spectrometry characterize chemical purity and identity. They do not measure biological activity, and no potency testing is performed or implied.

For laboratory research use only. Not for human or veterinary use.

Further reading